In a phase 2/3 trial investigating the efficacy of Keytruda with two chemotherapies, tumors shrank among 3 in 5 patients with pleural mesothelioma, Merck said May 29.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
Tumors shrink for 62% of patients in Merck study
